Summit Clinical Research Solutions Debuts Integrated CRO Powerhouse

SAN ANTONIO – May 27, 2026 – In a significant strategic move reflecting a broader industry shift toward consolidation and efficiency, Summit Clinical Research and Pinnacle Clinical Research have officially united under a new master brand: Summit Clinical Research Solutions. The announcement marks the creation of a fully integrated clinical research organization (CRO) designed to offer a comprehensive, end-to-end ecosystem for drug development sponsors.

The new entity aims to tackle one of the most persistent challenges in modern medicine: the operational fragmentation that can delay and complicate clinical trials. By combining their strengths, the organization intends to provide a streamlined, scalable model that accelerates trial execution from early-phase studies to global commercialization.

A New Blueprint for Clinical Research

At the heart of Summit Clinical Research Solutions' strategy is the integration of five distinct but coordinated platforms, each targeting a critical stage of the clinical trial lifecycle. This structure is engineered to function as a single, connected ecosystem, replacing the often-siloed approach that requires sponsors to manage multiple vendors and partners.

The five pillars of the new organization are:

• Pinnacle: A network of 14 integrated research sites, already recognized as a leader in high-demand therapeutic areas such as Metabolic dysfunction-associated steatohepatitis (MASH), obesity, and Alzheimer's disease.
• Elevation: An integrated research organization (IRO) service that extends the company's reach through a global partner-site network of 120 sites across eight countries, designed to support affiliated sites while preserving their local identities.
• Apogee: A centralized patient recruitment and enrollment platform focused on improving the speed, precision, and engagement of trial participants.
• Ascend: A medical communications and scientific strategy arm that supports sponsors through the complex processes of drug development and commercialization.
• Apex: A specialized unit providing early-phase CRO capabilities to support novel and complex therapeutic programs.

This unification formalizes a synergy that was already developing behind the scenes. "Bringing Summit and Pinnacle together under one brand reflects the way we already operate," said Mazen Noureddin, MD, MHSc, FAASLD. "Sponsors, sites, and partners already benefit from the integration of these capabilities. A unified Summit brand makes those capabilities easier to access, creates greater consistency across engagements, and strengthens our ability to support increasingly complex clinical development programs."

Targeting Bottlenecks with Proven Efficiency

A key differentiator for the newly unified company is its demonstrated prowess in patient enrollment, a notorious bottleneck in drug development that costs the industry billions in delays. Summit reports that across its supported studies, its affiliated sites—led by the Pinnacle network—contribute over 40% of all enrolled patients while making up only 25% of the participating trial sites. This impressive ratio points to a highly efficient and productive network.

This efficiency is not accidental but the result of a multi-pronged strategy. The Apogee platform provides a centralized engine for sophisticated patient outreach and engagement. This is combined with the deep therapeutic expertise embedded within the Pinnacle sites, allowing for more precise patient identification in complex diseases. The organization has also invested in initiatives to enhance diversity in clinical trials by building partnerships with community leaders and patient advocacy groups, ensuring trial populations better reflect the real world.

By minimizing screen failures and optimizing enrollment timelines, the integrated model aims to deliver the two things sponsors value most: speed and certainty. This focus on high-performance enrollment is a core component of Summit's value proposition in a competitive market.

Deep Expertise in High-Stakes Therapeutic Areas

Summit's strategy is anchored by its deep and established leadership in some of today's most challenging and prevalent diseases. The organization has positioned itself as the world's most experienced clinical trial network for MASH, a progressive liver disease with no approved therapies until recently. Since 2018, Summit has been a crucial partner for dozens of MASH trials, leveraging the scientific leadership of figures like Dr. Noureddin and the late Dr. Stephen Harrison, a pioneering liver researcher.

This specialization extends to other metabolic disorders, obesity, and central nervous system conditions like Alzheimer's disease. By concentrating its resources and expertise, Summit has built a formidable reputation, attracting sponsors developing next-generation therapies in these high-need areas. This focused approach allows the organization to cultivate strong relationships with key opinion leaders, develop specialized site capabilities, and maintain a deep understanding of the patient journey in each disease state, further enhancing its recruitment and execution capabilities.

Reshaping the Competitive CRO Landscape

The launch of Summit Clinical Research Solutions is a clear reflection of the ongoing consolidation within the CRO industry. As drug development becomes more complex and expensive, pharmaceutical and biotech sponsors increasingly prefer integrated partners who can manage the entire clinical trial process, reducing administrative burden and ensuring seamless data flow.

With its comprehensive five-platform model, Summit is positioning itself to compete directly with the largest players in the CRO space. The organization's scale—supporting over 50 sponsors across 115 trials since 2018—provides a solid foundation for future growth.

The move also has significant implications for the broader research ecosystem. For the 120 partner sites within the Elevation network, this unification promises greater access to resources, technology, and a more robust pipeline of clinical trials. Summit has been clear in its commitment to supporting these partners, reinforcing that its model is designed to empower, not absorb, its affiliated sites.

However, for independent sites not aligned with a major network, the rise of powerful integrated organizations like Summit represents a growing competitive pressure. The efficiency and scale of such entities could reshape market dynamics, compelling smaller players to either specialize in niche areas or seek partnerships to remain viable. By creating a model that aims to deliver superior results through integration, Summit Clinical Research Solutions is not just announcing a new brand; it is placing a strategic bet that could influence the future of how new medicines are developed.